Login to Your Account

Ready to file: Alkermes planning to submit NDA for antipsychotic in third quarter

By Michael Fitzhugh
Staff Writer

Tuesday, April 8, 2014

Alkermes plc said Tuesday that favorable phase III data on its long-acting injectable antipsychotic (LAI), aripiprazole lauroxil, will support its filing an FDA new drug application for the investigational schizophrenia treatment in the third quarter.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription